Evidence map›Paper›PMID 38352269›Full record

ArticleMolecular therapy. Methods & clinical development2024

Liter-scale manufacturing of shelf-stable plasmid DNA/PEI transfection particles for viral vector production.

Yizong Hu, Brendan A Eder, Jinghan Lin, Sixuan Li, Yining Zhu, Tza-Huei Wang, Ting Guo, Hai-Quan Mao

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yizong HuInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.
Brendan A Eder2seventy bio, Inc., Cambridge, MA 02142, USA.
Jinghan LinInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.
Sixuan LiInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.
Yining ZhuInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.
Tza-Huei WangInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.
Ting Guo2seventy bio, Inc., Cambridge, MA 02142, USA.
Hai-Quan MaoInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.

Funding

Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer ImmunotherapyR01CA281143 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jordan Green, Hai-Quan Mao · 2023 to 2026
$2.3M
NCI NIH HHS R01 CA281143
6 · The paper itself

Abstract

The transfection efficiency and stability of the delivery vehicles of plasmid DNA (pDNA) are critical metrics to ensure high-quality and high-yield production of viral vectors. We previously identified that the optimal size of pDNA/poly(ethylenimine) (PEI) transfection particles is 400-500 nm and developed a bottom-up assembly method to construct stable 400-nm pDNA/PEI particles and benchmarked their transfection efficiency in producing lentiviral vectors (LVVs). Here, we report scale-up production protocols for such transfection particles. Using a two-inlet confined impinging jet (CIJ) mixer with a dual syringe pump set-up, we produced a 1-L batch at a flow rate of 100 mL/min, and further scaled up this process with a larger CIJ mixer and a dual peristaltic pump array, allowing for continuous production at a flow rate of 1 L/min without a lot size limit. We demonstrated the scalability of this process with a 5-L lot and validated the quality of these 400-nm transfection particles against the target product profile, including physical properties, shelf and on-bench stability, transfection efficiency, and LVV production yield in both 15-mL bench culture and 2-L bioreactor runs. These results confirm the potential of this particle assembly process as a scalable manufacturing platform for viral vector production.

Indexed as

endosomal escapeHEK293 cellsnanoparticlesPEIplasmid DNApoly(ethylenimine)scale-up productiontransient transfection

Identifiers

PMID38352269
PMCPMC10863326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.